Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents.

Reinblatt SP, DosReis S, Walkup JT, Riddle MA.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):119-26. doi: 10.1089/cap.2008.040.

3.

Selective serotonin reuptake inhibitor-induced apathy: a pediatric case series.

Reinblatt SP, Riddle MA.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):227-33.

PMID:
16553543
4.

Spotlight on fluvoxamine in anxiety disorders in children and adolescents.

Cheer SM, Figgitt DP.

CNS Drugs. 2002;16(2):139-44. Review.

PMID:
11825104
5.

Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis.

Rausch JL, Hobby HM, Shendarkar N, Johnson ME, Li J.

J Clin Psychopharmacol. 2001 Apr;21(2):139-42.

PMID:
11270909
6.

Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.

Gothelf D, Rubinstein M, Shemesh E, Miller O, Farbstein I, Klein A, Weizman A, Apter A, Yaniv I.

J Am Acad Child Adolesc Psychiatry. 2005 Dec;44(12):1258-62.

PMID:
16292117
7.

Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.

Martin A, Koenig K, Anderson GM, Scahill L.

J Autism Dev Disord. 2003 Feb;33(1):77-85.

PMID:
12708582
8.

Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.

Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, Riddle M, Oatis M, Greenhill L, Skrobala A, March J, Gammon P, Robinson J, Lazell R, McMahon DJ, Ritz L; RUPP ADHD/Anxiety Study Group.

J Am Acad Child Adolesc Psychiatry. 2005 May;44(5):418-27.

PMID:
15843763
9.

[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].

OliƩ JP, Gourion D, Montagne A, Rostin M, Poirier MF.

Encephale. 2009 Dec;35(6):595-604. doi: 10.1016/j.encep.2009.10.011. Epub . French.

PMID:
20004291
10.

Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.

Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B.

Am J Psychiatry. 1999 May;156(5):756-60.

PMID:
10327910
11.

A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.

Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM.

J Clin Psychiatry. 2003 Jun;64(6):640-7.

PMID:
12823077
12.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
13.

Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study.

Walkup J, Labellarte M, Riddle MA, Pine DS, Greenhill L, Fairbanks J, Klein R, Davies M, Sweeney M, Abikoff H, Hack S, Klee B, Bergman RL, Lynn D, McCracken J, March J, Gammon P, Vitiello B, Ritz L, Roper M; Research Units on Pediatric Psychopharmacology Anxiety Study Group.

J Child Adolesc Psychopharmacol. 2002 Fall;12(3):175-88.

PMID:
12427292
14.

Blindness of clinical evaluators, parents, and children in a placebo-controlled trial of fluvoxamine.

Vitiello B, Davis M, Greenhill LL, Pine DS.

J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):219-25.

PMID:
16553542
15.

Fluvoxamine: a review of its therapeutic potential in the management of anxiety disorders in children and adolescents.

Cheer SM, Figgitt DP.

Paediatr Drugs. 2001;3(10):763-81. Review. Erratum in: Paediatr Drugs 2001;3(11):801.

PMID:
11706925
16.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
17.

Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study.

Asakura S, Tajima O, Koyama T.

Int J Neuropsychopharmacol. 2007 Apr;10(2):263-74. Epub 2006 Mar 30.

PMID:
16573847
18.

Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.

Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT.

J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):222-9.

PMID:
11211371
19.

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine.

van Vliet IM, den Boer JA, Westenberg HG.

Psychopharmacology (Berl). 1994 Jun;115(1-2):128-34.

PMID:
7862884
20.

Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.

Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.

J Clin Psychiatry. 1999 Sep;60(9):580-3.

PMID:
10520975
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk